SIM
FATE icon

Spark Investment Management’s Fate Therapeutics FATE Stock Holding History

Spark Investment Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-63,700
Closed -$114K – 804
2016
Q1 		$114K Buy
63,700
+1,100
+2% +$2.27K 0.01% 688
2015
Q4 		$210K Buy
+62,600
New +$263K 0.03% 570
2015
Q2 		– Sell
-12,800
Closed -$61K – 681
2015
Q1 		$61K Buy
+12,800
New +$63.4K 0.01% 662

Other funds holding FATE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return

Spark Investment Management's FATE Position: Q2 2016 in Review

Spark Investment Management sold out of Fate Therapeutics (FATE) in Q2 2016, closing a stake of 63,700 shares — an estimated $114K sold.

Spark Investment Management first reported a position in FATE in Q1 2015 and held it in 3 quarters. The position peaked at $210K in Q4 2015. 39 funds tracked by Wall St. Rank hold FATE as of Q2 2016.

  • Spark Investment Management reported no remaining Fate Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Spark Investment Management sold 63,700 Fate Therapeutics shares in Q2 2016, an estimated $114K.
  • Spark Investment Management first reported a position in Fate Therapeutics in Q1 2015 and held it in 3 quarters.
  • Spark Investment Management's Fate Therapeutics position peaked at $210K in Q4 2015.
  • 39 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2016.

Based on Spark Investment Management's 13F filing for Q2 2016, filed 12 Aug 2016.